Mechanistically, previous studies proved that ARID1A expression loss activates the PI3K/Akt pathway to induce oncogenic effects in multiple malignancies, including gastric cancer [16], gynecological cancers [17–19] and lung cancer [7]. This evidence concerns the gene ARID1A and lung carcinoma.